Illumina (ILMN) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Illumina (ILMN) right now is Installed base and the consumables annuity: Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. Revenue (FY2025) is ~$4.34 billion (approximate, verify). If that keeps playing out, the setup is favourable; the risk to it is competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. No one can predict where ILMN trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Illumina (ILMN) higher?
1. Installed base and the consumables annuity.
Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. Sequencing consumables revenue was about $755 million in the fourth quarter of 2025, up 8% year over year and roughly 11% excluding China. As long as customers keep running these machines, consumables provide a relatively sticky, high-visibility revenue stream.
2. The NovaSeq X transition.
The high-throughput NovaSeq X drives lower cost per genome and higher consumables volume as it replaces older systems. Illumina reported the installed base reaching roughly 890 instruments by the end of 2025, with the research transition nearly complete and clinical conversion past two-thirds. Each placement seeds future consumables demand, so the pace of conversion matters to the growth story.
3. Multiomics and clinical diagnostics.
Beyond DNA sequencing, Illumina is expanding into proteomics, single-cell, and spatial methods, and is leaning into clinical applications such as comprehensive genomic profiling in oncology and whole-genome sequencing in genetic disease. Clinical consumables excluding China grew about 20% in the fourth quarter of 2025, a faster-growing mix the company is trying to enlarge.
4. Margin recovery.
After the GRAIL distraction and a cost-reduction program, Illumina is targeting improved profitability. For fiscal 2026 it guided to a non-GAAP operating margin in roughly the 23.3% to 23.5% range, with operating margin around 22% reported in the first quarter of 2026. Continued margin expansion is a key part of how the company frames its earnings recovery.
What could weigh on ILMN?
Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk.
How to think about a ILMN forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ILMN guide and whether ILMN is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ILMN outlook
The bottom line: what is driving Illumina (ILMN) is Installed base and the consumables annuity, with revenue (fy2025) at ~$4.34 billion (approximate, verify). If that keeps playing out the setup is favourable; the risk is competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. No one can predict the price, so treat any ILMN forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ILMN with Walnut
Use Illumina as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Illumina (ILMN)?
+
No one can reliably predict where ILMN will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Illumina higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ILMN higher?
+
The main growth drivers are Installed base and the consumables annuity; The NovaSeq X transition; Multiomics and clinical diagnostics. Whether they play out is the real question, not a guaranteed path.
What are the risks to ILMN?
+
Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk.
Will ILMN stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Illumina's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ILMN a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ILMN "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.